NEW DELHI, JUNE 12 — Essential lifelines for cancer patients, tetanus treatments, and pediatric immunization programs will cost more following a series of emergency pricing interventions by the National Pharmaceutical Pricing Authority on Thursday. The central regulator rolled back restrictive price caps on several life-saving therapies to keep pharmaceutical companies from halting production due to unsustainable overhead costs.
The decision allows a 50% one-time surge for the foundational chemotherapy drugs Cisplatin and Carboplatin. The regulatory intervention followed assessments of raw material trends showing that surging global platinum costs had severely impacted industrial margins, leading to widespread hospital supply bottlenecks.
The revised pricing structure establishes the ceiling rate of Carboplatin 10 mg/ml at ₹90.74 per ml and Cisplatin 1 mg/ml at ₹10.89 per ml. An expert panel reviewed cost data spanning the last five years before recommending the expansion, determining that maintaining artificially low retail prices would jeopardize patient access to primary oncology drugs.
The pricing authority noted that its core mandate requires a careful balance between consumer affordability and the physical availability of therapies. The regulator clarified that the adjusted rates serve as a corrective mechanism to secure the supply chain, with an official review scheduled within the next six months to evaluate any further shifts in raw material expenses.
Socio-economic factors also prompted an upward price revision for anti-tetanus immunoglobulin vials distributed by Bharat Serums & Vaccines Limited. The manufacturer had challenged a previous pricing model that carried a standard monopoly-reduction penalty, asserting that import costs and manufacturing inflation made the formulation financially unviable to supply. The pricing watchdog agreed to restructure the limits, setting the new ceiling at ₹1,912.02 for 250 IU injections and ₹2,881.19 for 500 IU doses.
Additionally, the regulatory authority revised the costs of routine childhood immunizations supplied by the Serum Institute of India. Following administrative reviews that deemed generic price-reduction formulas inappropriate for complex biological products, the watchdog removed a 17.10% deduction while factoring in the latest wholesale price index. Consequently, the ceiling for the BCG vaccine rose to ₹9.89, the Measles-Rubella combination to ₹87.93, and the Measles vaccine to ₹62.00 per vial.
The pricing agency affirmed that strict regulatory oversight will continue alongside the higher price ceilings. Manufacturers planning to stop production of any of these essential formulations must give a mandatory six-month advance notice to the government, and retailers are legally required to display updated pricing charts prominently at all distribution points.
